Huntington's Disease Research
Huntington's disease is a neurodegenerative disease characterized by cognitive decline and motor dysfunction. It is a genetic disorder which results in the production of mutant huntingtin protein (mHtt). This protein aggregates in the cell cytoplasm and nucleus, affecting cellular function.
Huntington's Disease Research Products Targets
- Adenosine A2A Receptor (11)
- Caspase (9)
- Ubiquitin-activating Enzyme E1 (3)
- Ubiquitin E2 Conjugating Enzyme (3)
- Ubiquitin E3 Ligase (10)
- Deubiquitinating Enzyme (12)
- Hsp90 (10)
- Hsp70 (4)
- Glutamate (Metabotropic) Group III Receptor (26)
- Glutamate (Metabotropic) Group II Receptor (33)
- Glutamate (Metabotropic) Group I Receptor (54)
- Vesicular Monoamine Transporter (4)
- Sir 2-like Family Deacetylase (9)
- Post-Translational Modification (11)
- NMDA Receptor (87)
- Kainate Receptor (22)
- IP3 Receptor (2)
- ERK (6)
- D2 Receptor (14)
- D1 and D5 Receptor (16)
- Calpain (7)
- Trk Receptor (13)
- Autophagy (44)
- Antioxidant (19)
- Glutamate Transporter (18)
- Dopamine Transporter (20)
- Cathepsin (9)
- Mitochondrial Permeability Transition Pore (3)
- Proteasome (5)
- Histone Deacetylase (19)
- Histone Acetyltransferase (4)
Products for Huntington's Disease Research - Page 12
- Cat.No. Product Name Information/Activity
-
BCC7121
SKF 83566 hydrobromide
108179-91-5
-
BCC5034
Aripiprazole
Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.
-
BCC1417
B-HT 920
Talipexole dihydrochloride (B-HT 920 dihydrochloride) is a dopamine D2 receptor agonist, α2-adrenoceptor agonist and 5-HT3 receptor antagonist, which displays antiParkinsonian activity.
-
BCC7818
GSK 789472 hydrochloride
1257326-24-1
-
BCC1908
Rotigotine hydrochloride
Rotigotine Hydrochloride (N-0923 Hydrochloride) is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Ki of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.
-
BCC4112
Sumanirole maleate
Sumanirole maleate (U-95666E; PNU-95666E) is a highly selective D2 receptor full agonist with an ED50 of about 46 nM. Sumanirole was developed for the treatment of Parkinson's disease and restless leg syndrome.
-
BCC6886
L-741,626
L-741626 is a selective D2 dopamine receptor antagonist, with the Ki values of 2.4, 100 and 220 nM for human D2, D3 and D4 receptors respectively.
-
BCC7385
Melperone hydrochloride
1622-79-3
-
BCC5042
Olanzapine
Olanzapine is a selective monoaminergic antagonist with high affinity binding to serotonin H1, 5HT2A/2C, 5HT3, 5HT6 (Ki=7, 4, 11, 57, and 5 nM, respectively), dopamine D1-4 (Ki=11 to 31 nM), muscarinic M1-5 (Ki=1.9-25 nM), and adrenergic α1 receptors (Ki=19 nM). Olanzapine is an atypical antipsychotic.
-
BCN5339
Quetiapine fumarate
Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects.


